ICCC
ImmuCell Corporation
Biotechnology · Healthcare · United States
9.94
close · 2026-08-28
value
80
cheaper than peers80
quality
73
stronger fundamentals73
ranked against
Biotechnology (commercial)
value
quality
151 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 3.00× | 88 |
| price to book | 2.88× | 68 |
| EV to EBITDA | 13.08× | 58 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 26.9% | 90 |
| return on equity | 2.6% | 81 |
| revenue growth | 11.5% | 43 |
| debt to equity | 39.7% | 35 |
4 of 4 measures available
Facts
| market cap | $90M |
| free cash flow | $2.8M |
| employees | 73 |
| first trade | 1987-05-05 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-08-19 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.12 | -0.26 | -0.75 | -0.32 |
| free cash flow | $1.2M | -$107,822 | -$6.6M | -$5.5M |
| net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M |
| revenue | $27.6M | $26.5M | $17.5M | $18.6M |
| unusual items | -$2.3M | -$15,391 | $357,028 | $7,334 |